Using Policy to Reduce Opioids by Educating and Empowering Patients With Chronic Non-cancer Pain: The TAPERING Randomised Trial.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Inappropriate Dose of Drug Administered
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
- Enrollment
- 4255
- Locations
- 1
- Primary Endpoint
- Complete cessation of opioids
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
To assess the effectiveness of a government-led population-based opioid intervention on discontinuation of opioid medication in community-dwelling adults with chronic non-cancer pain.
Investigators
Cara Tannenbaum
Professor in the faculties of Medicine and Pharmacy, University of Montreal
Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
Eligibility Criteria
Inclusion Criteria
- •Adults registered to receive pharmaceutical benefits in Manitoba, who are aged 18 years and over and who have received ≥90 days supply of opioids in the 6 months prior to the trial will be included. This will ensure chronic use and episodic use of opioids will be included.
Exclusion Criteria
- •People receiving palliative care, people with cancer, and people who receive opioids in hospital. People with dementia (identified by having received a prescription for memantine or a cholinersterase inhibitor in the previous 12 months) will be excluded.
Outcomes
Primary Outcomes
Complete cessation of opioids
Time Frame: 6 months
Provincial prescription insurance claims will be used to measure whether or not opioids are dispensed to community-dwelling adults randomized to either the intervention or control groups between baseline and 6-month follow up. Prescription data contain information on all dispensed prescriptions including drug name, dispensing date, dosage, drug form, the quantity of the drug dispensed, and the license number of the physician who wrote the prescription. Discontinuation of an opioid will be defined as the lack of a prescription claim for at least 60 days.
Secondary Outcomes
- Dose reduction or therapeutic switch to an alternate analgesic(6 months)
- The proportion of people achieving opioid doses below 90mg oral morphine equivalents.(6 months)